Cytovia, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cytovia, Inc. - overview
Location
Irvine, CA, US
Primary Industry
Pharmaceuticals
About
Cytovia, Inc. is a biopharmaceutical company focused on developing advanced therapeutic cell solutions for oncology and autoimmune diseases, aiming to leverage the body’s immune system to enhance treatment efficacy. Cytovia, Inc. specializes in innovative cell therapies that target cancer and autoimmune disorders.
The company has undergone strategic changes since its establishment and is headquartered in Irvine, US. In June 2000, Cytovia was acquired by Maxim Pharmaceuticals. The firm has engaged in 2 different funding rounds, with the latest round raising USD 10. 00 mn, contributing to a total amount raised of USD 10.
00 mn. Cytovia is advancing therapeutic solutions in the biopharmaceutical sector, particularly through innovative cell therapies targeting oncology and autoimmune diseases. Their offerings aim to utilize the immune system to fight malignant cells, improving patient outcomes. The company caters to a diverse clientele, including research institutions, healthcare providers, and pharmaceutical firms, mainly in North America, Europe, and select regions in Asia.
Their end users are patients facing serious health challenges. Cytovia generates revenue through strategic partnerships and collaborations with healthcare organizations, research institutions, and biotechnology companies. They engage in B2B collaborations that include licensing agreements and joint development partnerships, allowing shared access to their proprietary cell therapies. Revenue streams emerge from upfront fees, milestone payments, and royalties tied to the commercial success of their therapies.
Cytovia plans to expand its product line by introducing new cell therapies targeting specific cancers and autoimmune disorders, with anticipated launches in the next few years. They are looking to penetrate additional markets, particularly in Europe and Asia, by 2025. Recent funding from the latest round will be utilized to support these initiatives and enhance research capabilities, driving forward their mission to improve treatment options for patients.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.cytovia.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.